{"id":"https://openalex.org/W2035866144","doi":"https://doi.org/10.1517/13543784.2013.847088","title":"Discontinued drugs in 2012: oncology drugs","display_name":"Discontinued drugs in 2012: oncology drugs","alternate_titles":[],"publication_year":2013,"publication_date":"2013-10-08","ids":{"openalex":"https://openalex.org/W2035866144","doi":"https://doi.org/10.1517/13543784.2013.847088","mag":"2035866144","pmid":"https://pubmed.ncbi.nlm.nih.gov/24102323"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.2013.847088","doi":"https://doi.org/10.1517/13543784.2013.847088","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2013.847088","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2035866144"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Robert Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Robert Williams","raw_affiliation_strings":["Cancer Research UK, Drug Development Office , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900 ; robert.williams@cancer.org.uk","Cancer Research UK, Drug Development Office, Angel Building, 407 St John Street, London EC1V 4AD, UK +44 203 469 6900"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Research UK, Drug Development Office , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900 ; robert.williams@cancer.org.uk","institution_ids":["https://openalex.org/I2801316944"]},{"raw_affiliation_string":"Cancer Research UK, Drug Development Office, Angel Building, 407 St John Street, London EC1V 4AD, UK +44 203 469 6900","institution_ids":["https://openalex.org/I2801316944"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2801316944"],"apc_list":null,"apc_paid":null,"fwci":6.9005,"has_fulltext":false,"cited_by_count":41,"citation_normalized_percentile":{"value":0.9633695,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"22","issue":"12","first_page":"1627","last_page":"1644"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.6538000106811523,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.6538000106811523,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.20080000162124634,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.020400000736117363,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.8169999718666077},{"id":"https://openalex.org/keywords/oncology-drugs","display_name":"oncology drugs","score":0.8920000195503235},{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.9890000224113464},{"id":"https://openalex.org/keywords/phase-iii-trial-failure","display_name":"phase III trial failure","score":0.8730000257492065},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.9909999966621399},{"id":"https://openalex.org/keywords/drug-development-efficiency","display_name":"drug development efficiency","score":0.6060000061988831},{"id":"https://openalex.org/keywords/new-drug-approvals","display_name":"new drug approvals","score":0.7319999933242798}],"concepts":[{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.6722537279129028},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6705905795097351},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6327687501907349},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5503734946250916},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.4984567165374756},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46622326970100403},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4544733464717865},{"id":"https://openalex.org/C3020340455","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Cancer drugs","level":3,"score":0.4378964900970459},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4027058780193329},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38892215490341187},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.2013.847088","doi":"https://doi.org/10.1517/13543784.2013.847088","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2013.847088","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:24102323","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24102323","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6240000128746033}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W2035140525","https://openalex.org/W2037356096","https://openalex.org/W2057335441","https://openalex.org/W2058298068","https://openalex.org/W2065174092","https://openalex.org/W2103146352","https://openalex.org/W2166550586","https://openalex.org/W2295843667","https://openalex.org/W2756717034","https://openalex.org/W2918127665","https://openalex.org/W4232914613"],"related_works":["https://openalex.org/W2024838010","https://openalex.org/W2057335441","https://openalex.org/W2547441676","https://openalex.org/W2158713870","https://openalex.org/W1588959571","https://openalex.org/W2412502577","https://openalex.org/W2149471179","https://openalex.org/W2172258043","https://openalex.org/W2793917881","https://openalex.org/W4286298900"],"abstract_inverted_index":{"This":[0],"year's":[1],"analysis":[2],"of":[3,34,48,74,88,91,108,116,128,151,171],"discontinued":[4,52,118],"drugs":[5,11,53,76,117],"in":[6,17,26,61,78,102,119,125,148],"oncology":[7],"reports":[8],"on":[9],"29":[10],"dropped":[12],"from":[13],"the":[14,21,62,92,103,114,126,129,149],"global":[15],"pipeline":[16],"2012.":[18],"Similar":[19],"to":[20,41,55,84,112,165,168],"trends":[22],"that":[23,139],"were":[24,29,82],"observed":[25],"2011,":[27],"there":[28,141],"a":[30,57,86],"large":[31],"number":[32],"(13)":[33],"Phase":[35,50,79,93],"I":[36,51],"terminations":[37],"reported,":[38],"largely":[39],"due":[40],"strategic":[42],"or":[43],"unspecified":[44],"reasons.":[45],"Only":[46],"one":[47],"these":[49,97],"appeared":[54],"incorporate":[56],"patient":[58],"stratification":[59,100],"biomarker":[60,71],"study":[63],"design":[64],"and":[65,121,161],"only":[66],"four":[67],"studies":[68,95],"incorporated":[69,99],"pharmacodynamic":[70],"analysis.":[72],"Out":[73],"seven":[75],"failing":[77],"III,":[80],"six":[81],"reported":[83],"display":[85],"lack":[87],"efficacy.":[89],"None":[90],"III":[94],"investigating":[96],"agents":[98],"biomarkers":[101],"trial":[104],"design.":[105],"The":[106],"aim":[107],"this":[109],"article":[110],"is":[111,137,142],"highlight":[113],"cohort":[115],"2012":[120],"discuss":[122],"their":[123],"profile":[124],"context":[127],"evolving":[130],"paradigm":[131],"for":[132,146],"anticancer":[133],"drug":[134,152,173],"development.":[135],"It":[136],"noteworthy":[138],"while":[140],"clearly":[143],"still":[144],"room":[145],"improvement":[147],"efficiency":[150],"development,":[153],"increased":[154,169],"collaboration":[155],"among":[156],"academics,":[157],"industry,":[158],"regulators,":[159],"government":[160],"not-for-profit":[162],"organisations":[163],"appears":[164],"be":[166],"contributing":[167],"numbers":[170],"new":[172],"approvals.":[174]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2035866144","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
